Calypte und die Zeit nach AIDS2004 in Bangkok
Seite 179 von 203 Neuester Beitrag: 19.01.06 14:27 | ||||
| Eröffnet am: | 05.07.04 15:03 | von: Kade_I | Anzahl Beiträge: | 6.056 |
| Neuester Beitrag: | 19.01.06 14:27 | von: Der_wahre_. | Leser gesamt: | 188.298 |
| Forum: | Hot-Stocks | Leser heute: | 144 | |
| Bewertet mit: |  | |||
| Seite: < 1 | ... | 177 | 178 | | 180 | 181 | ... 203 > | ||||
Optionen
| Boardmail an "Kade_I" |
Wertpapier: Calypte Biomedical |
Optionen
| Boardmail an "Kade_I" |
Wertpapier: Calypte Biomedical |
Seit langem wieder hohe Umsätze.
Kade gut das du wieder dich meldest ; ) .
Die machen das so spannend die Jungs, das ich kaum abwarten kann auf die presentation...
Gruß
C.O
Grüße, ZN
Wovon gehst du denn aus ??
Deine behauptungen mußt du doch hinterlegen können,überzeuge uns doch davon,zumindest der versuch ist es doch Wert uns zu überzeugen..
Gruß
C.O
Und ausserdem wollt Ihr doch gar nicht wirklllich überzeugt werden, stimmts. Ich wünsche euch jedenfalls fette Gewinne auch wenn ich -wie gesagt- daran nicht mehr glauben kann.
Grüße, ZN
Grüße, ZN
für DICH ist das Thema Caly-Investm. jedenfalls erledigt,aber für viele fängt es erst an.
Vergiss nicht jede geplante Investition zahlt sich aus..
Gruß
C.O
...jede geplante investition zahlt sich aus....prust...du meinst: muß sich auszahlen, so ist zumindestens deine wunschvorstellung...wie bei den anderen auch, die bis oberkante unterlippe in dem dreck stecken...
wer hier nicht Ernst genommen wird ist doch klar..
Wenn der 911 er da ist kannst du damit auch fahren versprochen..
Gruß
C.O
selbst von micha höre ich nichts mehr. ich hätte ihn aber auch vom intellekt her so eingeschätzt, dass er es irgendwann einmal kapiert...auch andere haben sich gedanken gemacht. von zeit zu zeit bekomme ich gewisse boardmails, entweder hier oder bei W:O...wo sich gewisse leute dann einsichtig und geläutert zeigen...
broker, du wirst nach deinem untergang hier nur noch mit dem fiat 500 davon fahren...
We believe that the BED Incidence test can also provide policy makers and
program managers with valuable insights regarding the success of their
prevention programs and a scientific approach to both human and financial
resource allocation. Incidence estimates help determine the efficacy of
prevention programs from both a disease spread and financial resource
perspective and evaluate areas appropriate for alternative therapeutic media,
such as vaccine trials. We expect the demand for this product to grow throughout
2005 as the CDC continues to conduct worldwide workshops to train
representatives from various governmental public health and humanitarian
organizations to use the test.
STATUS OF NEW PRODUCTS
HIV-1/2 RAPID TESTS
Our primary focus is developing and commercializing new test products for the
rapid detection of antibodies to HIV-1 and HIV Type 2, a second type of HIV
("HIV-2") in blood, oral fluid and urine samples using a lateral flow dipstick
design (the "HIV-1/2 Rapid Tests"). We are currently conducting clinical trials
of these products in the People's Republic of China ("China"), Uganda and South
Africa and expect to conduct other trials during 2005. Pending local regulatory
approval, we expect to have the blood test commercially available early in the
second quarter of 2005 and the non-blood tests available before the seond half
of this year.
The largest numbers of cases of HIV are found in sub-Saharan Africa and Asia. It
is predicted that the next wave of the epidemic may occur in China, India, and
in the countries of Northern Africa and Eastern Europe. The characteristics of
these markets make adoption of our laboratory-based ELISA tests a difficult
challenge. In vast areas of Africa and Asia in particular, the lack of properly
equipped laboratories, properly trained technologists, or even reliable
electricity and water make the logistics associated with traditional
laboratory-based testing algorithms slow, impractical and unreliable.
Self-contained rapid tests that are easy to perform even in remote locations
seem to offer tremendous promise in these high-risk settings.
Furthermore, one of the challenges faced by clinicians around the world is that
of getting patients to return to the testing clinic for their HIV test results
several days or weeks after their initial counseling and testing session. The
CDC has reported that up to 30% of the people who attend HIV clinics in the
United States do not return for their results, and whether this is caused by
fear or by the inconvenience of revisiting the clinic, the result is the same -
lost opportunities to further counsel, and if necessary, treat the public. The
problem is no better in the developing world.
Unfortunately, HIV testing in the developing world often requires a more
comprehensive solution than a reliable point-of-care test, however. Cultural
taboos about giving blood, the fear of painful blood collection, the risks
associated with the re-use or accidents involving needles and lancets, and the
stigma of being seen at an HIV clinic are all factors that can limit the utility
and effectiveness of rapid HIV tests.
The ability to perform HIV testing without the need for a blood sample has been
shown in the past to significantly increase voluntary testing rates. Moreover,
the elimination of needles and lancets from the testing process simultaneously
eliminates the risk of accidental infection through needle re-use or
needle-stick accident. This apparent need for rapid HIV antibody tests that can
be performed safely and painlessly on non-blood samples in virtually any setting
drove our development of rapid HIV tests for urine and oral fluid samples, in
addition to the traditional blood/serum/plasma format.
7
Page 9
OF OPERATIONS
The following information should be read in conjunction with the consolidated
financial statements and related notes that are provided under Part II, Item 7
of this Annual Report on Form 10-KSB. The information contained in this
management's discussion and analysis of financial condition and results of
operations ("MD&A"), other than historical information, contains "forward
looking statements" within the meaning of The Private Securities Litigation
Reform Act of 1995 that are based on management's current expectations and
assumptions. Actual future results could differ materially. This MD&A should
also be read in conjunction with the sections entitled "Additional Factors That
May Affect Future Results" and "Forward-Looking Statements."
OVERVIEW AND OUTLOOK
Our financial objective is to achieve profitable growth. Management believes
that by providing a combination of test products, we will be able to increase
revenues. Our efforts in 2003 and 2004 have been primarily focused on developing
new test products and acquiring the intellectual property needed to develop
those products. Our efforts in 2004 have included reducing operating expenses by
closing our Alameda, California manufacturing facility and consolidating the
production of our ELISA tests in our Rockville manufacturing facility. We have
increased our overall investment in research and development. These research and
development expenditures have enabled us to introduce new and enhanced test
products. Subject obtaining adequate financing, we plan to continue to focus our
efforts in 2005 on improving our operating and gross margins, commercializing
our products and expanding our product offerings.
Sales of our ELISA tests totaled approximately $2.8 million in 2004 and $3.5
million in 2003. Sales to international customers accounted for approximately
16% and 15% of our product sale revenues in 2004 and 2003, respectively.
Guidance Our focus for 2005 is on the commercialization of our HIV-1/2
rapid test, initially in a dipstick-format and produced in Thailand. We have
begun clinical trials in Uganda and South Africa and expect to begin additional
trials during 2005 in several other African countries, including South Africa.
While there are different regulations and customs in each foreign country, we
have distribution relationships in place in several countries that will be part
of these next trials and we believe that the regulatory process can generally be
completed in a few months. Therefore, we expect to begin African and perhaps
southeast Asian sales in mid-2005. We are unable to predict with any certainty
the magnitude of such sales in 2005.
We have also begun clinical trials in China and have received initial feedback
from the field that leads us to believe that all three of our HIV-1/2 rapid
tests, blood, oral fluid and urine, plus our serum and urine Western Blot
supplemental tests will meet the accuracy standards that have been employed by
the Chinese regulatory authorities in approving other HIV rapid tests. The
statistical report assessing firm conclusions from the clinical trials is
expected to be issued in the second quarter of 2005. In parallel with the
regulatory approval process, we have continued to advance our manufacturing
strategy. We expect to have production available to support a commercial product
launch in China subsequent to regulatory approval during the second half of
2005. There are several large markets in China, including a recently announced
commitment by the Chinese government to offer voluntary HIV testing to its
entire 1.36 billion population. With trained non-professionals and a safe,
non-invasive alternative fluid - oral fluid or urine - testing program employing
the products currently involved in the clinical trial, we expect strong demand
for our products. Beijing Calypte, our joint venture with Marr, will manage the
Chinese rapid test product launch. We are unable to predict with any certainty
the magnitude of rapid test sales in China, if any, in 2005.
Additionally, we believe that the Ani Platform provides us with an alternative
product format with potential applicability in both the professional and OTC
markets worldwide. We do not, however, expect to generate any revenues from
products utilizing the Ani Biotech technology in 2005.
In addition to the rapid test, we believe the Incidence Test to be a
complementary product that can provide policy makers and program managers with
valuable insights regarding the success of their prevention programs and a
scientific approach to resource allocation. We expect the demand for this
product to grow throughout 2005 as the CDC continues to conduct worldwide
workshops to train representatives from various governmental public health and
humanitarian organizations to use the test. At this time, we are unable to
predict with any certainty the level of incidence test sales in 2005, but expect
them to begin modestly early in the year and expand at an increasing rate in the
second half of 2005. Additionally, we have begun the research on a blood-based
rapid HIV incidence test for diagnostic and surveillance purposes under the
terms of a Cooperative Research and Development Agreement with the CDC. Based on
the developmental and regulatory timetables we project for this product, we do
not expect to realize any revenue from its sale in 2005.
33
Page 35
As of March 29, 2005, 171,207,589 shares of the registrant's common stock,
$.03 par value, were outstanding.
Sales of our ELISA tests totaled approximately $2.8 million in 2004 and $3.5
million in 2003. Sales to international customers accounted for approximately
16% and 15% of our product sale revenues in 2004 and 2003, respectively.
The
statistical report assessing firm conclusions from the clinical trials is
expected to be issued in the second quarter of 2005.
In parallel with the
regulatory approval process, we have continued to advance our manufacturing
strategy. We expect to have production available to support a commercial product
launch in China subsequent to regulatory approval during the second half of
2005.
Although we issued a
$2,000,000 Promissory Note (the "Promissory Note") to Marr in January 2005, it
was due on March 31, 2005 and the proceeds have not provided us with the
liquidity to fully attain our business milestones and to achieve profitability.
We have negotiated an extension of the maturity date of the Promissory Note
until April 30, 2005.
Our current cash resources are not sufficient to sustain
our operations and achieve our milestones through the second quarter of 2005
without obtaining additional financing. We believe that we will need to arrange
additional financing of approximately $15 million to sustain our operations
throughout 2005, including the funds required to repay the Promissory Note.
ELISA Test Sales Sales of our urine ELISA Screening and Supplemental Tests
accounted for 55% and 67% of our total product sales for the years ended
December 31, 2004, and 2003, respectively. We do not expect significant changes
in the level of sales or the purchasers of our current urine EIA screening and
supplemental tests in the near future.
Years Ended December 31, 2004 and 2003
Calypte's revenues for 2004 totaled $3.3 million compared with $3.5 million for
2003, a decrease of $0.2 million or 5%. Urine EIA screening test revenues
decreased by $686,000 or 32% to $1,481,000 in 2004 compared with $2,167,000 in
2003. Urine Western Blot sales generally follow a trend similar to that of the
screening test and decreased $85,000 or 55%, from $154,000 in 2003 to $69,000 in
2004.
International sales of our EIA screening tests accounted for approximately
$16,000 and $173,000 in 2004 and 2003, respectively. Our primary international
sales in 2003 were to our Chinese distributor.
Gross margin decreased from a loss of $2,654,000 (-77% of sales in 2003) to a
loss of $3,981,000 (-142% of sales in 2004) as a result of three primary
factors
Research and development costs increased by $596,000 or 39%, from $1,544,000 in
2003 to $2,140,000 in 2004.
Selling, general and administrative costs decreased by $6,538,000 or 42%, from
$15,517,000 in 2003 to $8,979,000 in 2004.
MUHAHAHAHAHA
das wichtigste im grossen und ganzen.
aber broker wird euch erklären, warum die zahlen trotzdem gut sind und wird seienn freund kade zu rate ziehen!!!
die zahlen sind so grottenschlecht, wie erwartet
ich sage nur: be aware of caly!!!!
ich lasse euch jetzt wieder mit eurem scherbenhaufen alleine.
gute nacht!
sinkende absatzzahlen!!!!
kaum mehr cash!!!
hohe kostenquote!!!
derbe verluste!!!
keine großaufträge!!!
darauf lege ich mich jetzt fest: es wird dieses jahr keine großaufträge mehr geben, wie ich euch schon sagte. jetzt träumt schön von eurer phantasie.
aber ihr wisst ja:
truth is stronger than fiction!!